R. Faroux

发表

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

R. Labianca, M. Ducreux, J. Taïeb, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

T. Conroy, M. Ychou, E. Assenat, 2018, Journal of Clinical Oncology.

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.

A. Lièvre, P. Laurent-Puig, C. Borg, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

M. Ychou, J. Douillard, F. Goldwasser, 2012, Clinical colorectal cancer.

EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST”

J. Douillard, N. Padilla, J. Raoul, 2016 .

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.

F. Retornaz, J. Seitz, T. André, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2011, International journal of cancer.

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2009, British Journal of Cancer.

Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC)

T. Conroy, M. Ychou, M. Ducreux, 2007 .

First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study.

J. Taieb, C. Coutzac, S. Pernot, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

J. Douillard, G. Milano, M. Etienne-Grimaldi, 2012, British journal of clinical pharmacology.

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

T. Conroy, M. Ychou, M. Ducreux, 2011, Oncology.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

C. Borel, C. Lepage, V. Boige, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combinations of Cytochrome P450 Gene Polymorphisms Enhancing the Risk for Sporadic Colorectal Cancer Related to Red Meat Consumption

S. Küry, B. Buecher, V. Sébille, 2007, Cancer Epidemiology Biomarkers & Prevention.

Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma.

O. Bouché, J. Seitz, J. Jouve, 2019, Journal of hepatology.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

O. Bouché, F. Retornaz, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in ‘true life’: a plea in favor of independent postmarketing evaluations

C. Renou, A. Pariente, J. Cadranel, 2010, European journal of gastroenterology & hepatology.

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

K. Boudjema, E. Assenat, C. Lombard-Bohas, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focus.

J. Douillard, J. Metges, Z. Alavi, 2020, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

O. Bouché, F. Retornaz, J. Taieb, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

A. Lièvre, M. Ducreux, C. Lepage, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.

C. Tournigand, R. Guimbaud, O. Bouché, 2019, European journal of cancer.

473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

M. Ychou, G. Deplanque, Y. Bécouarn, 2017 .

EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

T. Conroy, M. Ychou, M. Ducreux, 2007 .

The thorough screening of the MUTYH gene in a large French cohort of sporadic colorectal cancers.

S. Küry, S. Olschwang, B. Buecher, 2007, Genetic testing.

Increased incidence of Campylobacter enteritis and their quinolone resistance between 2010 and 2015: Results of a French national observatory conducted in 21 general hospitals (CHG).

X. Causse, D. Poisson, B. Denis, 2019, Clinics and research in hepatology and gastroenterology.

Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.

C. Borel, V. Boige, O. Bouché, 2016 .

High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease

J. Hugot, B. Bonaz, J. Rey, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308.

I. Sobhani, B. Dousset, D. Péré-Vergé, 2014, European journal of cancer.

Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis

T. Conroy, M. Ychou, M. Ducreux, 2005 .

Prevention of 5-FU-induced health-threatening toxicity by pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach.

C. Borg, J. Metges, E. Gamelin, 2013 .

O-0019 Severe Fluoropyrimidines Toxicities: A Simple and Effective Way to Avoid Them. Screen Effectively for DPD Deficiencies.

J. Metges, E. Gamelin, A. Morel, 2012 .

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

O. Bouché, A. Bedjaoui, F. Retornaz, 2018, European journal of cancer.

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

J. Taïeb, S. Olschwang, V. Boige, 2022, Therapeutic advances in medical oncology.

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

P. Laurent-Puig, M. Ychou, G. Deplanque, 2019, Annals of Oncology.

Comparison of 4 Screening Methods for Detecting Fluoropyrimidine Toxicity Risk: Identification of the Most Effective, Cost-Efficient Method to Save Lives

M. Campone, J. Metges, O. Capitain, 2020, Dose-response : a publication of International Hormesis Society.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Lecomte, Sophie Gourgou, T. Conroy, 2018, The New England journal of medicine.

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.

A. Lièvre, M. Ychou, O. Bouché, 2016, Clinical colorectal cancer.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials

T. Hickish, R. Salazar, J. Tabernero, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Middle-term mortality and re-bleeding after initial diverticular bleeding: A nationwide study of 365 mostly elderly French patients

A. Pariente, S. Nahon, P. Lahmek, 2017, United European gastroenterology journal.

High-Density of FcγRIIIA+ (CD16+) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis

J. Mosnier, S. Bézieau, M. Péré, 2021, Frontiers in Oncology.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

C. Reinhold, C. Borel, C. Lepage, 2019, Gut.

Microscopic Colitis or Functional Bowel Disease With Diarrhea: A French Prospective Multicenter Study

A. Pariente, S. Nahon, P. Lahmek, 2014, The American Journal of Gastroenterology.

Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.

E. Assenat, A. Bertaut, F. Bonnetain, 2017 .

A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.

J. Raoul, J. Metges, E. Gamelin, 2017, Seminars in oncology.

[Multicenter prospective study of prognostic factors of gastroduodenal ulcer hemorrhages. Reevaluation of clinical and endoscopic factors in the era of endoscopic hemostasis].

C. Jacquelinet, D. Heresbach, J. Bretagne, 2000, Gastroentérologie Clinique et Biologique.

Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases.

Y. Deugnier, J. Raoul, P. Bourguet, 1988, Radiology.

Risk factors for hepatocellular carcinoma in Caucasian patients with non‐viral cirrhosis: the importance of prior obesity

D. Samuel, P. Nahon, L. Planche, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

C. Borg, J. Metges, E. Gamelin, 2017, Seminars in oncology.

Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study

S. Küry, B. Buecher, V. Sébille, 2008, BMC Cancer.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.

I. Sobhani, O. Boulat, O. Bouché, 2017, European journal of cancer.

Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.

M. Buyse, M. Ychou, P. Rougier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Ultraflex precision colonic stent placement for palliation of malignant colonic obstruction: a prospective multicenter study.

G. Costamagna, C. Hervoso, S. Meisner, 2007, Gastrointestinal endoscopy.

Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.

A. Lièvre, J. Taieb, S. Pernot, 2019, European journal of cancer.

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.

C. Lombard-Bohas, O. Bouché, F. Bonnetain, 2009, European journal of cancer.

Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study

A. Pariente, S. Nahon, R. Faroux, 2012, Endoscopy.

The Characteristics of Diverticular Disease in Caribbean Population: A Control Group Study

A. Schneck, J. Dimet, R. Faroux, 2022, Canadian Journal of Gastroenterology & Hepatology.

LBA29Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

E. Assenat, A. Bertaut, F. Bonnetain, 2017 .

LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

M. Ychou, E. Assenat, O. Bouché, 2021, Annals of Oncology.

DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

R. Greil, R. Salazar, P. Laurent-Puig, 2016, JAMA oncology.

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

C. Lepage, G. Deplanque, V. Bourcier, 2021, Hepatology International.

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

J. Douillard, H. Naman, P. Piedbois, 2007, British Journal of Cancer.

PROGNOSIS OF UPPER GASTROINTESTINAL BLEEDING IN THE OLDEST‐OLD PATIENTS: A POST HOC ANALYSIS OF A PROSPECTIVE STUDY

A. Pariente, S. Nahon, R. Faroux, 2010, Journal of the American Geriatrics Society.

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer

R. Guimbaud, P. Soulié, L. Mineur, 2020, PloS one.

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics

J. Douillard, P. Langlet, E. Jobard, 2014, Oncologie.

The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

Y. Bécouarn, O. Bouché, F. Bonnetain, 2016 .

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2020 .

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001-01 CHOC)

C. Lombard-Bohas, O. Bouché, F. Bonnetain, 2005 .

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

M. Loriot, J. Thariat, O. Bouché, 2019, Bulletin du cancer.

Corrigendum to 'Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study': Annals of Oncology 2020; Volume 31: 921-929.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of Oncology.

Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting.

X. Paoletti, P. Rougier, C. Lombard-Bohas, 2011, Journal of hepatology.

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

P. Laurent-Puig, J. Galon, A. Duval, 2019, Journal of Clinical Oncology.

DPYD Genotyping to Predict Adverse Events Following TreatmentWith Fluorouracil-Based Adjuvant Chemotherapy in PatientsWith Stage III Colon Cancer

R. Greil, R. Salazar, P. Laurent-Puig, 2016 .

Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.

A. Lièvre, J. Taieb, S. Pernot, 2021, Clinics And Research in Hepatology and Gastroenterology.

Prognostic factors associated with upper gastrointestinal bleeding based on the French multicenter SANGHRIA trial

D. Heresbach, L. Tsakiris, Margot Laly, 2021, Endoscopy International Open.

Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

S. Olschwang, V. Boige, O. Bouché, 2016 .

A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).

C. Tournigand, R. Guimbaud, Anu Gupta, 2017 .

Safety analysis of the French Intergroup R98 trial comparing 5FU-leucovorin alone or with irinotecan in resected stages II-III rectal cancers

M. Ychou, P. Rougier, J. Douillard, 2008 .

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

A. Lièvre, C. Lepage, O. Bouché, 2016 .

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial.

C. Lepage, O. Bouché, D. Pezet, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).

V. Boige, O. Bouché, F. Ghiringhelli, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).

G. Piessen, O. Bouché, C. Eveno, 2019, Journal of Clinical Oncology.

Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting

T. Conroy, M. Ychou, M. Ducreux, 2007 .

585 A FRENCH MULTICENTRIC LONGITUDINAL DESCRIPTIVE STUDY OF HEPATOCELLULAR CARCINOMA MANAGEMENT (THE CHANGH COHORT): PRELIMINARY RESULTS

X. Causse, T. Decaens, C. Renou, 2010 .

Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study

A. Pariente, S. Nahon, R. Faroux, 2012, Endoscopy.

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.

F. Pruvot, M. Ychou, F. Bonnetain, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

H. Naman, P. Piedbois, J. Delord, 2007, British Journal of Cancer.

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)--A randomized phase II trial.

O. Bouché, F. Retornaz, J. Taieb, 2015 .